Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)

Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)

Abstract The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matche...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisabetta Pupillo, Elisa Bianchi, Ettore Beghi, Francesco Andrea Pedrazzini, Angela Giglio, Edoardo Dalmato Schilke, Marco Percetti, Carlo Morotti Colleoni, Gabriele Mainini, Paolo Calabresi, Guido Primiano, Giovanni Frisullo, Alessandro Padovani, Viviana Cristillo, Andrea Pilotto, Davide Arici, Stefano Gipponi, Gioacchino Tedeschi, Alessandro d’Ambrosio, Rosario Domenico Melisi, Antonio Gallo, Alvino Bisecco, Andrea Salmaggi, Paola Basilico, Chiara Scaccabarozzi, Lorenzo Kiferle, Raffaella Valenti, Gianluca Avino, Annamaria Borghi, Sara Contardi, Andrea Zini, Carlo Ferrarese, Simone Beretta
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
COVID-19
Vaccines
Case-control study
Epidemiology
Attributable risk
Neurological disorders
Online Access:https://doi.org/10.1038/s41598-025-88837-0
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29–0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years ( p = 0.0472; OR 0.14, 95% CI 0.03–0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01–0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02–0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies.
ISSN:2045-2322

Similar Items